Treace Medical Concepts Inc. is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus. Treace Medical Concepts Inc. is based in PONTE VEDRA, Fla.
| Revenue (Most Recent Fiscal Year) | $209.36M |
| Net Income (Most Recent Fiscal Year) | $-55.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.78 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -22.89% |
| Net Margin (Trailing 12 Months) | -22.89% |
| Return on Equity (Trailing 12 Months) | -49.49% |
| Return on Assets (Trailing 12 Months) | -24.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.60 |
| Inventory Turnover (Trailing 12 Months) | 1.09 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 63.72M |
| Free Float | 46.05M |
| Market Capitalization | $170.76M |
| Average Volume (Last 20 Days) | 1.25M |
| Beta (Past 60 Months) | 0.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 27.72% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |